幽门螺杆菌抗生素耐药:全球挑战与解决方案探索
该国际调查覆盖6大洲31个国家,评估幽门螺杆菌抗生素耐药率、药敏检测、药物可及性与报销及监测策略。
要点
- 克拉霉素和左氧氟沙星耐药分别在24/31和18/31国家超过15%。
- 仅4/26国家建立耐药监测规划,多数国家采用局部经验性治疗。
核心结论
- 全球幽门螺杆菌抗生素耐药急剧上升,迫切需要修订当前管理策略。
- 可能的解决方案包括基于药敏检测选择有效方案、鉴定现有药物的新组合以及探索新药。
研究设计与样本
- 在6大洲31个国家开展的国际调查,旨在收集和更新幽门螺杆菌抗生素耐药率及管理策略信息。
- 调查内容涵盖特定抗生素耐药率、不同医疗体系中抗生素药敏检测、药物可及性、报销问题及耐药监测策略。
主要发现
- 克拉霉素耐药在24/31国家超过15%,左氧氟沙星耐药在18/31国家超过15%。
- 阿莫西林耐药率在14/31国家低于2%,但非洲国家报告阿莫西林耐药率超过90%。
- 基于PCR的耐药检测在16/26国家使用但仅4国报销,二代测序检测在3国可用但均不报销。
- 仅培养法在22/26国家可用(其中9/26国家报销),耐药监测规划仅在4/26国家建立。
关键数值与推荐
- 铋剂治疗方案最有效,在多个国家被推荐为一线治疗。
- 在多数国家,采用当地可获得的最有效方案进行经验性治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Helicobacter pylori resistance to antibiotics commonly used in eradication regimens is increasing dramatically in many locations; new strategies are needed to manage this infectious disease. OBJECTIVE: This study's aim was to collect and update information on antibiotic resistance (AR) rates in H. pylori as well as current strategies for H. pylori management, including public health issues, from a global perspective. DESIGN: An international survey was conducted in 31 countries on 6 continents to address key issues concerning the management of H. pylori-related AR. Individual aspects included the prevalence of AR for specific antibiotics, antibiotic susceptibility testing (AST) in different healthcare systems, availability of drugs, reimbursement issues and strategies for H. pylori AR surveillance. RESULTS: Resistance to the most effective antibiotics used in H. pylori eradication regimens is increasing globally, with clarithromycin and levofloxacin resistance exceeding 15% in 24/31 and 18/31 countries, respectively. Amoxicillin remains an exception, with resistance rates under 2% in 14/31 countries; though African countries have reported amoxicillin resistance rates of over 90%. Bismuth-based treatment regimens are the most effective and are recommended as first-line treatment in several countries. However, more than 1 billion inhabitants worldwide have no access to bismuth-based regimens. PCR-based tests for AR are used in 16/26 countries but are reimbursed in only 4, while next generation sequencing-based tests are available, but not reimbursed, in 3 countries. In 22/26 countries only culture-based methods are available (reimbursed in 9/26 countries). AR surveillance programmes have only been established in 4/26 countries. Therefore, in most countries, empirical therapy with the most effective local regimen available locally is practiced. CONCLUSION: The dramatic global rise in H. pylori antibiotic resistance requires an urgent revision of current management strategies. Possible solutions include AST-based selection of effective treatment regimens, identification of novel combinations of existing drugs and exploration of novel drugs.
引用
- Schulz C, Liou JM, Alboraie M, et al. Helicobacter pylori antibiotic resistance: a global challenge in search of solutions. Gut. 2025. PMID: 40645767. doi:10.1136/gutjnl-2025-335523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。